Nadroparin is a low molecular weight heparin used for the prophylaxis of thrombotic events and deep vein thrombosis, and prevent unstable angina and non-Q-wave myocardial infarction. Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa.
- Mechanism
- Curator reviewed
The mechanism of action for nadroparin is similar to all other LMWHs. Like all LMWHs, nadroparin has a pentasaccharide sequence which binds to ATIII, which potentiates the action of ATIII. This complex greatly accelerates the inactivation of factor Xa and factor IIa. As a result, the coagulation cascade is inhibited.
- Primary indication
- Nadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction.Curator reviewed · 13 structured indications
- First approval
- Canada, 2026
- Also known as
- Nadroparine
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Nadroparin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account